Cabaletta Bio
CABA
139 hedge funds and large institutions have $490M invested in Cabaletta Bio in 2026 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 50 increasing their positions, 20 reducing their positions, and 23 closing their positions.
2,128% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $781K
770% more capital inflows, than outflows
Capital inflows: $273M | Capital outflows: $31.4M
150% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 20
135% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 23
29% more funds holding
Funds holding: 108 → 139 (+31)
20.76% more ownership
Funds ownership: 76.06% → 96.82% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$36.4M |
| 2 |
BlackRock
New York
|
+$27.6M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$25.6M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$24.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$12.6M |
| 2 |
Two Sigma Investments
New York
|
-$3.57M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.02M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.67M |
| 5 |
Renaissance Technologies
New York
|
-$1.65M |
CABA Hedge Fund Activity: Q2 2026 in Review
139 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q2 2026, worth a combined $490M — up 116% from $228M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new CABA positions and 23 closed out — a net gain of 31 holders — while 50 added to existing stakes and 20 trimmed.
The largest buyer was Jennison Associates, adding an estimated $36.4M. The largest seller was Millennium Management, cutting an estimated $12.6M.
- 139 institutional investors held Cabaletta Bio (CABA) as of Q2 2026, up from 108 in Q1 2026.
- Funds reported $490M of Cabaletta Bio stock for Q2 2026, up 116% quarter-over-quarter.
- 54 funds opened new Cabaletta Bio positions in Q2 2026 and 23 closed out, a net change of +31 holders.
- The largest Cabaletta Bio buyer in Q2 2026 was Jennison Associates, an estimated $36.4M added.
- The largest Cabaletta Bio seller in Q2 2026 was Millennium Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2026.